🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

314 results for “cells” Clear

  1. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Ovarian Carcinoma

    phase 2 mab active

    1 trial

  2. Cytokine-induced killer cells

    The First People's Hospital of Lianyungang

    Melanoma

    phase 2 mab active

    1 trial

  3. DCVax-L and T Cells

    NORTHWEST BIOTHERAPEUTICS INC

    Ovarian Cancer

    phase 2 mab terminated

    1 trial

  4. Dexamethasone 4 mg tablets, Cytarabine 20 mg/ml Solution for Injection or Infusion, Calquence 100 mg hard capsules, Cyclophosphamide 500 mg Powder for Solution for Injection or Infusion, Fludarabine phosphate 25 mg/ml Concentrate for Solution for Injection or Infusion, Histergan Tablets, Tecartus 0.4 - 2 x 10e8 cells dispersion for infusion, Mesna Injection, Methylprednisolone 1000 mg powder and solvent for solution for injection/infusion, RoActemra 20 mg/mL concentrate for solution for infusion, Panadol 50

    Lacuna Pharma Pty Ltd

    Relapsed/Refractory Mantle Cell Lymphoma

    phase 2 small molecule active

    1 trial

  5. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial

  6. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial

  7. EBV-TCR-T (YT-E001) cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 2 mab active

    1 trial

  8. EBV-specific T cells (EBV-CTLs)

    Evidence Based Cataract Study Group

    EBV-induced Lymphomas

    phase 2 mab completed

    1 trial

  9. Expanded , Activated NK cells

    Hospital Authority, Hong Kong

    Ewing Sarcoma

    phase 2 mab active

    1 trial

  10. Guttmann NeuroRecovery – Feasibility, safety and efficacy of intrathecal Wharton's jelly-derived mesenchymal stem cells and transcutaneous spinal cord stimulation in the rehabilitation of chronic spinal cord injuries: a pilot study

    The George Institute

    Traumatic spinal cord injury

    phase 2 other active

    1 trial

  11. HS_SW01 cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Primary Ovarian Insufficiency (Poi)

    phase 2 small molecule active

    1 trial

  12. HS_SW01 cells injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Ankylosing Spondylitis

    phase 2 small molecule active

    1 trial

  13. HiPSC-RPE cells

    The First People's Hospital of Lianyungang

    AMD - Age-Related Macular Degeneration

    phase 2 mab active

    1 trial

  14. Human Mesenchymal Stromal Cells

    United Therapeutics Europe Ltd

    Respiratory Distress Syndrome, Adult

    phase 2 mab completed

    1 trial

  15. Humanized CD7 CAR-T cells

    The First People's Hospital of Lianyungang

    T Lymphoblastic Leukemia/Lymphoma

    phase 2 mab active

    1 trial

  16. IL-15-armored CAR-T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Multiple Myeloma

    phase 2 mab active

    1 trial

  17. Induction of neo-antigen specific T cells by specialized cross-presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC study

    Disc Medicine

    Ovarian cancer

    phase 2 other active

    1 trial

  18. Infusion of autologous mononuclear bone marrow cells

    Lxo Ireland Designated Activity Company

    Idiopathic Dilated Cardiomyopathy

    phase 2 small molecule terminated

    1 trial

  19. Infusion of mesenchymal stem cells from adipose tissue

    Lxo Ireland Designated Activity Company

    Faecal Incontinence

    phase 2 small molecule completed

    1 trial

  20. Injectable suspension of allogeneic adult mesenchymal stem cells

    Lxo Ireland Designated Activity Company

    Hidradenitis Suppurativa

    phase 2 mab active

    1 trial

  21. Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells

    The First People's Hospital of Lianyungang

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  22. Intraarterial infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Critical Limb Ischemia (CLI)

    phase 2 other completed

    2 trials

  23. Intracoronary infusion of autologous bone marrow cells

    Lxo Ireland Designated Activity Company

    Dilated Cardiomyopathy

    phase 2 other completed

    1 trial

  24. JNJ-68284528, CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusion

    Janssen-Cilag International N.V.

    Newly Diagnosed Multiple Myeloma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources